Combination therapy with sorafenib or regorafenib and troxacitabine phosphoramidate prodrug

摘要

Sorafenib or regorafenib and the formula: [Wherein Y is C ₁ -C ₈ linear or branched alkyl, X is H, halo, C ₃ -C ₄ cycloalkyl or C ₁ -C ₄ alkyl, and Z is H or A combination therapy with a phosphoramidate prodrug of toloxacitabine, or a pharmaceutically acceptable salt thereof, having a fluoro] has surprising utility in the treatment of liver cancer or liver metastases.